Patients & Caregivers
Combining knowledge, empathy, and science to empower patients to live their lives.
Combining knowledge, empathy, and science to empower patients to live their lives.
We understand that while significant advances have been made in treating rare diseases like hereditary angioedema (HAE), there is still much to be done. Specifically, we believe that scientific advances will usher in a new era of oral medications with the potential to address unmet needs and empower people in their everyday lives.
The perspective of the HAE community—your perspective—is at the heart of everything we do.
July 7, 2025
Today marks a historic milestone for the hereditary angioedema (HAE) community: the U.S. Food and Drug Administration (FDA) has approved the first oral on-demand treatment for HAE attacks. This approval ushers in a new era for how this disease can be managed, empowering people to treat HAE attacks wherever they are when they happen—no needles, no pain and no need to delay treatment.
Your voices, experiences, and partnership have helped shape this therapy from its earliest development to today’s approval. We are deeply grateful to the people living with HAE, caregivers, healthcare professionals, and advocacy organizations who have made this possible, especially the HAEA and HAEi for their steadfast collaboration and commitment to the community.
We know that living with HAE means navigating unpredictability, anxiety, and at times, pain and disruption. Our goal has always been clear: to develop a treatment that helps people respond quickly to HAE attacks—one that’s effective, safe, and easy to use. With this approval, we’re proud to offer an option that we hope fits into daily life and has the potential to bring peace of mind to those who need it.
We also understand that access is just as important as innovation. That’s why we’ve launched KalVista Cares, a comprehensive patient support program in the U.S., designed to guide patients through every step of their treatment journey. From navigating insurance to personalized services and financial assistance, our team is here to help make care easier, more accessible and less stressful.
While today marks a major milestone, our work is far from done. KalVista remains committed to partnering with the HAE community: listening, learning, and continuing to improve care together.
Thank you for being a part of this journey and allowing us to be a part of yours.
With gratitude,
Benjamin L. Palleiko
Chief Executive Officer
KalVista Pharmaceuticals
In collaboration with the U.S. Hereditary Angioedema Association (HAEA), we asked 107 members of the community about their experience with HAE attacks. Here’s what we learned.
According to HAE treatment guidelines, on-demand treatment remains the foundation of HAE management. Yet, all too often, the burdens associated with current injectable treatments make them challenging to carry and use, causing people to miss the opportunity to treat at symptom onset, when HAE attack progression could be halted. Survey data underscores that oral new on-demand solutions are needed, and an oral, rapid-onset therapy could change how people treat and experience HAE attacks.
We design our clinical trials with input from the HAE community. We learned from patients about how they experienced attacks, from recognition through progression and resolution. Our goal is to demonstrate therapeutic results in a way that is most impactful for people living with HAE.
Our commitment to HAE started 10 years ago and will continue into the next decade and beyond. Our scientists are inspired by the courage of all those in the HAE community who contribute to making new advancements possible.
YOU ARE NOW LEAVING KALVISTA.COM
You are now being directed to another KalVista website that contains information about specific treatment(s)